# Torrid

Type: Company (CURV)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/torrid
Canonical HTML page: https://gethealthbrief.com/entity/torrid

## Timeline

- **2026-12-01**: ASH Annual Meeting — Curis targets presentation of initial proof-of-concept data for the CLL study.
- **2026-06-30**: Torrid Store Closures — Target date for an additional 30 store closures by Torrid to reach savings goals.
- **2026-03-19**: Q4 Earnings Release — Curis, Torrid, Caleres, and Lands' End all report Q4 2025 results.
- **2026-01-15**: PIPE Financing — Curis secured initial $20.2M in PIPE proceeds to fund oncology pipeline development.
- **2025-11-01**: Erivedge Wind-down — Royalties from Erivedge began winding down, prompting the strategic sale to Oberland.

## Recent coverage (1 stories)

### Curis Secures Oncology Runway as Macro Headwinds Pressure Retail Margins
2026-03-20 00:40:26 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Curis (CRIS) has successfully pivoted to a clinical-stage oncology focus, securing a cash runway into 2027 through a strategic asset sale and PIPE financing. Meanwhile, broader retail earnings from Torrid and Caleres reveal significant margin pressures from tariffs, signaling a complex macro environment for healthcare supply chains.
Full story: https://gethealthbrief.com/story/curis-oncology-pivot-retail-macro-trends-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.